Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by enriquesuaveon May 03, 2023 9:23am
158 Views
Post# 35427165

RE:RE:RE:Trial Result Tables

RE:RE:RE:Trial Result Tables
Rumpl3StiltSkin wrote: Does the 90 day data in the swimmers plot include the 2 CRs from phase 1? If not then I don't think there are 2 discounted CRs in the swim plot data. I don't think there were any  of the 12 undertreated that were CR? Maybe a few of them were IR? So IF I'm correct the worst we will have is that 35% 450 day CR  Slayer came up with. :-)

In the initial 12 under treated, there were 3 CR patients and 3 PR patients at 90 days.  I can still see between 40-55% CR depending on how IR Patients are reclassified and also if new CRs appear after 2nd treatment when all is said and done.  Anything above 30% for only 2 treatments 6 months apart and minimal side effects is still way better than Keytruda and Adstiladrin or any other single agent to date.  IMHO 
<< Previous
Bullboard Posts
Next >>